Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.806 USD | -1.59% | -0.49% | -27.39% |
03-15 | Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-14 | Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.39% | 43.77M | D+ | ||
+8.69% | 220B | B | ||
+6.69% | 183B | B- | ||
+10.90% | 133B | B- | ||
+25.41% | 107B | A- | ||
+0.27% | 63.05B | A- | ||
+12.72% | 51.74B | B+ | ||
+3.96% | 50.47B | B+ | ||
+0.40% | 40.91B | A | ||
+15.03% | 40.59B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CTSO Stock
- Ratings Cytosorbents Corporation